- Home
- SWTX vs BLTE Comparison
SWTX vs BLTE Comparison
Compare SWTX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- BLTE
- Stock Information
- Founded
- SWTX 2017
- BLTE 2018
- Country
- SWTX United States
- BLTE United States
- Employees
- SWTX N/A
- BLTE N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- SWTX Health Care
- BLTE Health Care
- Exchange
- SWTX Nasdaq
- BLTE Nasdaq
- Market Cap
- SWTX 2.2B
- BLTE 2.1B
- IPO Year
- SWTX 2019
- BLTE 2022
- Fundamental
- Price
- SWTX $36.45
- BLTE $82.81
- Analyst Decision
- SWTX Strong Buy
- BLTE Strong Buy
- Analyst Count
- SWTX 5
- BLTE 4
- Target Price
- SWTX $65.40
- BLTE $89.00
- AVG Volume (30 Days)
- SWTX 1.3M
- BLTE 110.7K
- Earning Date
- SWTX 11-12-2024
- BLTE 11-12-2024
- Dividend Yield
- SWTX N/A
- BLTE N/A
- EPS Growth
- SWTX N/A
- BLTE N/A
- EPS
- SWTX N/A
- BLTE N/A
- Revenue
- SWTX $135,487,000.00
- BLTE N/A
- Revenue This Year
- SWTX $3,498.68
- BLTE N/A
- Revenue Next Year
- SWTX $98.08
- BLTE N/A
- P/E Ratio
- SWTX N/A
- BLTE N/A
- Revenue Growth
- SWTX N/A
- BLTE N/A
- 52 Week Low
- SWTX $20.19
- BLTE $31.01
- 52 Week High
- SWTX $53.92
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- SWTX 71.38
- BLTE 73.39
- Support Level
- SWTX $29.53
- BLTE $77.62
- Resistance Level
- SWTX $35.26
- BLTE $86.53
- Average True Range (ATR)
- SWTX 1.92
- BLTE 5.84
- MACD
- SWTX 0.74
- BLTE 0.69
- Stochastic Oscillator
- SWTX 87.38
- BLTE 88.01
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.